Pharmaceuticals Saudi Arabia

Saudi Arabia Exosome Therapeutics Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Saudi Arabia Exosome Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Application, Source, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Saudi Arabia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $4.1 Mn Placeholder estimate
Estimate 2025 $5.1 Mn 1.6% of the global market
Projected 2034 $42.8 Mn 735.4% Adds $37.7 Mn over 9 forecast years
CAGR 2025–2034 26.6% Faster than 94% of 180 Pharmaceuticals markets here
Key players 5 Companies profiled
  • Saudi Arabia is 1.64% of the global market.
  • In Middle East, the largest is Saudi Arabia (this report) at $5.1 Mn.
  • Fastest growing: Saudi Arabia (this report) at 26.6% a year.
  • Saudi Arabia ranks 1st of 2 by size in Middle East.

Market size projection

Saudi Arabia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$37.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Exosome Therapeutics Market market size by year, Saudi Arabia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $4.1 Mn — —
2025 (base) $5.1 Mn +$1.1 Mn —
2026 (forecast) $6.5 Mn +$1.4 Mn +26.6%
2027 (forecast) $8.2 Mn +$1.7 Mn +60.3%
2028 (forecast) $10.4 Mn +$2.2 Mn +102.9%
2029 (forecast) $13.2 Mn +$2.8 Mn +156.9%
2030 (forecast) $16.7 Mn +$3.5 Mn +225.2%
2031 (forecast) $21.1 Mn +$4.4 Mn +311.7%
2032 (forecast) $26.7 Mn +$5.6 Mn +421.2%
2033 (forecast) $33.8 Mn +$7.1 Mn +559.9%
2034 (forecast) $42.8 Mn +$9.0 Mn +735.4%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Saudi Arabia Exosome Therapeutics Market Analysis at a glance
Market size, 2025$5.1 Mn placeholder estimate
Forecast, 2034$42.8 Mn placeholder estimate
Growth (CAGR), 2025–203426.6% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsApplication, source and end user (see all)
Key playersCodiak BioSciences, Evox Therapeutics, Aegle Therapeutics, Capricor Therapeutics, ExoCoBio, Inc (see all)
Regulator in Saudi ArabiaSFDASource: Saudi Food and Drug Authority. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Saudi Arabia Exosome Therapeutics Market Analysis Executive Summary

Exosome therapeutics use tiny vesicles released by cells to carry drugs or healing signals, for cancer, inflammation and regenerative medicine.

Key segments of the exosome Therapeutics market include application (Drug Delivery, Regenerative Medicine and Diagnostics) and source (Stem Cell-Derived, Plant-Derived and Engineered).

Bar chart: Saudi Arabia Exosome Therapeutics market size, 2024–2034, placeholder estimates. $4.1 Mn in 2024, $5.1 Mn in 2025 and $42.8 Mn in 2034, 26.6% CAGR.
Saudi Arabia Exosome Therapeutics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Saudi Arabia Exosome Therapeutics Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the exosome Therapeutics market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the exosome Therapeutics market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the exosome Therapeutics market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for Exosome Therapeutics Market in Saudi Arabia

The exosome Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Exosome Therapeutics Market in Saudi Arabia

Exosome Therapeutics in Saudi Arabia: rules and payment

The Saudi Food and Drug Authority (SFDA) registers medicines before sale.⁠[1] Citizens get free public care through the Ministry of Health, while most expatriate workers must have private health insurance, regulated by the Council of Health Insurance (CHI).⁠[2]

[1] Saudi Food and Drug Authority. Checked 14 Nov 2026.

[2] Council of Health Insurance. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for exosome Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Saudi Arabia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Exosome Therapeutics right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Exosome Therapeutics in context

Saudi Arabia compared

  • Health spending per person: 1,825 US$ per person (2023). World: 1,317 US$ per person (2023). 2nd highest of the 9 countries we cover in Middle East.[1]
  • Doctors: 3.41 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). Highest of the 9 countries we cover in Middle East.[2]
  • People aged 65 and over: 3.1% of people (2025). World: 10.4% of people (2025). 6th highest of the 9 countries we cover in Middle East.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Exosome Therapeutics market in Saudi Arabia?
Placeholder estimate: about $5.1 Mn in 2025, rising to about $42.8 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Exosome Therapeutics market in Saudi Arabia growing?
Placeholder estimate: about 26.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Exosome Therapeutics market report cover?
The report splits the market by application (Drug Delivery, Regenerative Medicine, Diagnostics, Oncology), source (Stem Cell-Derived, Plant-Derived, Engineered) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Exosome Therapeutics market?
Key players include Codiak BioSciences, Evox Therapeutics, Aegle Therapeutics, Capricor Therapeutics and ExoCoBio, Inc.
What is driving the Exosome Therapeutics market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the exosome Therapeutics market.
Who regulates Exosome Therapeutics in Saudi Arabia?
The Saudi Food and Drug Authority (SFDA) registers medicines before sale. Source: Saudi Food and Drug Authority. Checked 14 Nov 2026.
How is healthcare paid for in Saudi Arabia?
Citizens get free public care through the Ministry of Health, while most expatriate workers must have private health insurance, regulated by the Council of Health Insurance (CHI). Source: Council of Health Insurance. Checked 14 Nov 2026.
How much research is published on Exosome Therapeutics?
PubMed lists 29 papers on Exosome Therapeutics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Saudi Arabia

See all

Related on biologics and biosimilars and genomics

See the topic